Gad Getz

Jun 13, 2024 | nature.com | Lindsay Morton |Olivia Lee |Stephen W. Hartley |Sara Schonfeld |Elizabeth K Cahoon |Vladimir Drozdovitch | +6 more

AbstractChildhood radioactive iodine exposure from the Chornobyl accident increased papillary thyroid carcinoma (PTC) risk. While cervical lymph node metastases (cLNM) are well-recognized in pediatric PTC, the PTC metastatic process and potential radiation association are poorly understood. Here, we analyze cLNM occurrence among 428 PTC with genomic landscape analyses and known drivers (131I-exposed = 349, unexposed = 79; mean age = 27.9 years).

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.

Aug 31, 2023 | nature.com | Caleb A Lareau |Leif S. Ludwig |Christoph Muus |Gad Getz |fei chen |Jason D. Buenrostro | +3 more

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-020-0645-6. Published online 12 August 2020. In the version of this article initially published, due to a coding error, cell clonotypes and allele frequencies were permuted, impacting the visualization of panels in Fig. 6i, j, k, and o. Corrected panels appear as Fig. 1 below, and the software and documentation listed in the Code availability section have been updated.

Jul 20, 2023 | nature.com | Gad Getz

AbstractChildren with acute lymphoblastic leukemia (ALL) undergoing anti-CD19 therapy occasionally develop acute myeloid leukemia (AML). The clonal origin of such lineage-switch leukemias1,2,3,4 remains unresolved. Here, we reconstructed the phylogeny of multiple leukemias in a girl who, following multiply relapsed ALL, received anti-CD19 cellular and antibody treatment and subsequently developed AML.

Apr 18, 2023 | lungcancer.einnews.com | Gad Getz |Nir Hacohen

One of the newest types of cancer drugs, immunotherapies called immune checkpoint inhibitors, has transformed the treatment of lung cancer over the last decade — dramatically improving the survival of some patients with the most common form of this disease, non-small cell lung cancer (NSCLC). However, only about 20 percent of patients experience a benefit from these immunotherapies.